Argenx announces initial ARGX-113 Phase 1 study results
6 January 2016 | By Victoria White
The objective of the Phase 1 study is to evaluate the safety and tolerability of ARGX-113 and to identify a potential dose for future Phase 2 studies...
List view / Grid view
News
Gilead’s TAF meets primary objectives in two Phase 3 HBV trials
6 January 2016 | By Victoria White
The studies demonstrated that TAF was non-inferior to Gilead’s Viread (tenofovir disoproxil fumarate, TDF) based on the percentage of patients with HBV DNA levels below 29 IU/mL at 48 weeks of therapy...
Real world study demonstrates effectiveness of biosimilar infliximab
6 January 2016 | By Victoria White
Newly presented data from the largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab...
Breast cancer treatment market to reach $17.2b by 2021, says GBI Research
5 January 2016 | By Victoria White
GBI Research states that this strong growth will be primarily due to substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise over the forecast period due to an aging population, changing lifestyles and higher survival rates...
FDA grants Orphan Drug Designation to IONIS-HTTRx
5 January 2016 | By Victoria White
IONIS-HTTRx is a Gen. 2.0+ antisense drug in development for the treatment of Huntington's disease...
MRSA treatment market to experience limited growth, says GlobalData
5 January 2016 | By Victoria White
The minimal increase over the next decade will be largely the product of a treatment space dominated by three primary agents, namely vancomycin, Zyvox (linezolid), and Cubicin (daptomycin)...
Celyad’s NKG2D CAR T-cell therapy completes 30-day safety follow-up
5 January 2016 | By Victoria White
CAR-NKG2D is a chimeric antigen receptor (CAR) T-Cell autologous therapy that has the potential to target ligands present on a broad range of solid tumours and blood cancers...
Positive results for Baremsis in Phase 3 PONV study
5 January 2016 | By Victoria White
Baremsis comprises a low dose intravenous formulation of the marketed dopamine antagonist amisulpride, which Acacia Pharma has repurposed for the management of PONV...
Trial to investigate avelumab and entinostat in ovarian cancer
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
MHRA warns of the dangers of buying diet pills online
4 January 2016 | By Victoria White
Since 2005, MHRA officials have found hundreds of examples of medicines claiming to contain herbal ingredients but after analysis were found to be adulterated with pharmaceutical ingredients...
Almirall exercises option to acquire 100% of ThermiGen
4 January 2016 | By Victoria White
ThermiGen is a privately held medical aesthetics technology company and a leading developer and manufacturer of thermistor-regulated energy systems for plastic surgery and aesthetics dermatology applications...
Gastric cancer treatment market to reach $4.4b by 2024
4 January 2016 | By Victoria White
GlobalData says this rise will be driven primarily by the introduction of premium-priced therapies for advanced gastric cancer and, as a consequence, the increased uptake of therapy and lengthier treatment duration...
TERS solution shows immediate results after installation
4 January 2016 | By HORIBA Scientific
Joint HORIBA and AIST-NT solution provided spatial resolution below 15 nm...
Existing drugs show promise as antibiotic agents
4 January 2016 | By Victoria White
University of Illinois researchers have found that a number of existing drugs approved for the treatment of various conditions, such as cancer or infertility, show promise as antibiotic agents...
Sanofi Pasteur’s Dengvaxia approved in Brazil
Dengvaxia was shown to reduce dengue due to all four serotypes in two-thirds of the participants in clinical trials and prevent 8 out of 10 hospitalisations due to dengue and up to 93% of severe dengue cases...
